menu search

HZNP / Horizon Therapeutics Public Limited Company (HZNP) Q3 2022 Earnings Call Transcript

Horizon Therapeutics Public Limited Company (HZNP) Q3 2022 Earnings Call Transcript
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP ) Q3 2022 Results Conference Call November 2, 2022 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Chief Investor Relations Officer Tim Walbert - Chairman, President and Chief Executive Officer Liz Thompson - Executive Vice President, Research & Development Aaron Cox - Executive Vice President and Chief Financial Officer Andy Pasternak - Executive Vice President, Chief Strategy Officer Conference Call Participants Chris Schott - JPMorgan Annabel Samimy - Stifel Madhu Kumar - Goldman Sachs Jason Gerberry - Bank of America Ken Cacciatore - Cowen David Risinger - SVB Securities LLC David Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Equity Research Amy Li - Jefferies Operator Good morning, and thank you for standing by. Welcome to the Horizon Therapeutics plc Third Quarter 2022 Earnings Conference Call. Read More
Posted: Nov 2 2022, 12:27
Author Name: Seeking Alpha
Views: 092016

HZNP News  

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

By Zacks Investment Research
August 28, 2023

Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit

The Federal Trade Commission suspends its ongoing lawsuit to block Horizon's (HZNP) acquisition by Amgen until Sep 18, 2023. The company's stock rises more_horizontal

Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger

By Investopedia
August 28, 2023

Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger

Horizon Therapeutics (HZNP) shares jumped more than 5.5% in early trading Monday after the FTC said it would suspend its challenge to Amgen's (AMGN) a more_horizontal

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

By Zacks Investment Research
August 9, 2023

Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales

Horizon (HZNP) reports better-than-expected second-quarter results, beating both earnings and sales estimates, with the top-line key contributors bein more_horizontal

Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics

By Zacks Investment Research
August 8, 2023

Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics

The headline numbers for Horizon Therapeutics (HZNP) give insight into how the company performed in the quarter ended June 2023, but it may be worthwh more_horizontal

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates

By Zacks Investment Research
August 8, 2023

Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates

Horizon Therapeutics (HZNP) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compare more_horizontal

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

By Zacks Investment Research
July 24, 2023

Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study

Horizon (HZNP) fails to meet the primary endpoint in the mid-stage study of evaluating daxdilimab in the treatment of systemic lupus erythematosus. more_horizontal

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

By Zacks Investment Research
June 2, 2023

Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? more_horizontal

Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'

By Seeking Alpha
May 29, 2023

Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'

Amgen's stock has seen a further pullback since it announced an acquisition of Horizon Therapeutics in December. Shares are down by nearly a quarter a more_horizontal


Search within

Pages Search Results: